> In the present study, we conducted an anti-AR efficacy and safety study of NVP-1703 in volunteers with AR. NVP-1703 treatment significantly alleviated the TNSS score of at week 1, 3 and 4 compared to the placebo group. In particular, NVP-1703 treatment significantly alleviated the watery rhinorrhea at week 1, 3, and 4 and nasal congestion at week 4 compared to the placebo-treated control group. Furthermore, in the evaluation of the RCAT questionnaire, NVP-1703 treatment alleviated the tear symptom, sleep disorder, and nasal congestion at 4 weeks. NVP-1703 treatment sustained IL-10 levels in the blood more highly than placebo treatment while the blood IgE and PGF2α levels significantly decreased in the NVP-1703 group compared to the placebo group. (논문결과 요약, 사이토카인등 요약 추가)

In the present study, we conducted an study on efficacy and safety of NVP-1703 in volunteers with AR. NVP-1703 significalty improved the clinical outcomes ch as TNSS and RCAT questionnare. NVP-1703 successfuuly alleviated watery rhinorrhea, nasal congestion and tear symptom and sleep disorder. In addition, NVP-1703 also significantly improved various anti-allergic immunologic files such as speific IgE for house dust mites, PGF2a as well as IL-10, IL-10/IL-4 ratio and IL-10/IL-5 ratio. These result of our study means that NVP-1703 can antagonize the key immunologic markers associated with allergic rhinitis, which in turn results the improvement of symptoms associated with allergic rhinitis.

> Clinical trials of various microbial resources such as probiotics for allergic rhinitis have been conducted worldwide. Most of these clinical trials evaluated the efficacies of probiotics in combination with anti-AR drugs. These studies have used the Quality of Life assessment rather than the TNSS evaluation. However, the Quality of Life assessment may be insufficient in accurately evaluating the efficacies of anti-AR drugs and probiotics. Therefore, we orally administered NVP-1703 alone without rescue medications and its anti-AR efficacy was evaluated using TNSS, RCAT, and allergic cytokine analysis. Nevertheless, NVP-1703 significantly alleviated TNSS and RCAT scores and allergic cytokine levels. NVP-1703, the probiotic mixture of Bifidobacterium longum IM55, which was selected from human gut bacteria collection as an regulatory T cell regulator, and Lactobacillus plantarum IM76, which was from the fermented food bacteria collection as a macrophage NF-κB inhibitor, significantly regulates innate and adaptive immunity in animal and in vitro studies [27,28]. (우리논문은 TNSS RCAT 둘다 측정해서 좋은 결과를 보였다, 뭐 이런 멘트가 빠졌습니다)

probiotics를 통해 allergic rhinitis를 치료해보고자하는 많은 시도들이 있었다. 하지만 본 연구는 다음과 같은 장점이 있다. 대부분의 연구들이 비염에 대해 항히스타민제와 같은 anti-AR medication을 유지하면서 probitiocs의 부가적인 효과에 대해서 임상시험을 진행하였다. 하지만 우리들은 현재 allergic rhinitis에 대한 증상이 지속적으로 충분한 환자들에 대해서, 다른 anti-allergic rhinitis medication을 중단한 상태에서 순수히 NVP-1703이 allergic rhinitis 증상을 호전시킬 수 있는지 알아보았다. 또한 이전의 다른 연구들은 TNSS와 같은 rhinitis symptom에만 초점을 맞춰서 연구를 진행하였다. 하지만 본 연구는 TNSS와 같은 rhinitis symptom 뿐만 아니라 RCAT와 같은 quality of life assoaciated with rhinitis에 대해서도 연구하였다. 본 연구에서 경구로 투약된 NVP-1703은 anti-AR medication을 사용하지 않고 있는 상태에서, 충분한 비염증상이 있는 환자들을 대상으로 rhinitis에 대한 증상 호전뿐만 아니라, 삶의 질 또한 동시에 호전키실 수 있음이 증명되었다. 현재까지 NVP-1703은 anti-AR medication을 하지 않은 상태에서 symptomatic allergic rhinitis 환자에서 효과가 증명된 첫번째 probiotics이다. 

현재까지 allergic rhinitis에 대한 probiotics의 효과들은 consistency하지 않았다. Allergic rhinitis 관련해서 주로 Bifidobacterium과 lactobacillus 계열 probiotics들에 대한 연구가 진행되었다. 몇몇 Bifidobacterium lactis, Bifodibaterium longum, lactobacillus plantatrum, Lactobacillus paracasei 등의 probiotics에 대한 연구에서는 allergic rhinitis 관련해서 비염의 일부증상에서 효과가 있었다고 보고했다. 하지만 동일한 균주를 가지고 유사한 디자인으로 시행된 연구에서 효과가 없다고 보고된 바도 있다. 최근에는 동물실험 등을 통해 anti-allergic effect가 있다고 밝혀진 probiotics 균주를 mix해서 투약하려는 시도들이 있었다. Miraglia 등은 비염 환자에게 Bifidobacterium 균주 3가지 (Bifidobacterium longum BB536, Bifidobacterium infantis M63, and Bifidobacterium breve M-16V)를 투약하였고 RQLQ score 및 nasal symptoms의 partial improvement가 있다고 보고하였다. 이번 연구에서는 기존 allergic rhinitis에 효과가 있다는 보고가 있었던 Bifidobacterium longum, Lactobacillus plantarum 두가지 균주를 섞어서 투약하였다. (왜 두가지 균주를 섞어서 실험을 했는지? 같은 균주의 2개를 섞는 것과 다른 어떠한 장점이 있을 수 있는지?)
본 실험을 통해 확인된 NVP-1703의 효과는 향후 allergic disease와 관련된 probiotics의 effect를 알아보고자 할 때 한가지 균주 또는 같은 strain의 유사 균주를 섞는 것보다 synergistic한 effect를 보일 수 있는 몇가지 다른 섞는 것이 더 효과적일 수 있음을 보여준다. 

> Bifodibacterium lactis, Lactobacillus gasseri, Lactobacillus salivarium, Bactobacillus acidophilus, Bifidobacterium longum, Lantobacillum plantarum, Lactobacillus paracasei, Lactobacillus paracasei, 
> Mixture of Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium breve 


> In the present study, we also found that blood IL-10 levels were significantly higher in the NVP-1703 group than in the placebo group, which showed a statistical significance between the groups. Furthermore, NVP-1703 treatment reduced blood IL-4, IL-5, and IL-13 levels. The ratios of IL-10/IL-4, IL-10/IL-5, and IL-10/IL-13 were increased in the NVP-1703-treated group but decreased in the placebo-treated group. The administration of NVP-1703 significantly suppresses the expression of IL-4 and IL-5 and the differentiation of T cells into Th2 cells in mice with ovalbumin (OVA)- and house dust mite allergen extract (HDMA)-induced AR, while the expression of IL-10 and the differentiation of T cells into Treg cells are increased [27,28]. These results suggest that the administration of NVP-1703 can suppress the expression of Th2 cytokines IL-4 and IL13 and eosinophil cytokine IL-5 by inducing the IL-10 expression, a Treg cell cytokine, and Treg cell differentiation. Tomiita et al reported that the ratio of IL-10/IL-5 was significantly increased in a healthy control group when compared to active asthma and remission groups [42]. Aslam et al. reported that immunotherapy in patients with wasp-vinon allergy increased the ratio of IL-10/IL-4 [43]. 

> We also found that NVP-1703 inhibited IgE levels, particularly Df- and Dp-secific IgEs, in the blood of individuals with AR. IL-10 indirectly facilitates IL-4-induced IgG4 production in human B cells together with the suppression of IgE [44]. IL-10 inhibits IgE-induced activation of human mast cells directly in vitro [45]. The induction of IL-10 expression suppresses the expression of IgE receptors in mast cells [46]. There results suggest that the induction of IL-10 expression by NVP-1703 can suppress the production of IgE including Dp- and Df-specific IgE production. The NVP-1703-treated group also showed a significant decrease in PGF2 in the urine compared to the placebo group after 4 weeks of ingestion.

> We also found that NVP-1703 inhibited IgE levels, particularly Df- and Dp-secific IgEs, in the blood of individuals with AR. IL-10 indirectly facilitates IL-4-induced IgG4 production in human B cells together with the suppression of IgE [44]. IL-10 inhibits IgE-induced activation of human mast cells directly in vitro [45]. The induction of IL-10 expression suppresses the expression of IgE receptors in mast cells [46]. There results suggest that the induction of IL-10 expression by NVP-1703 can suppress the production of IgE including Dp- and Df-specific IgE production. The NVP-1703-treated group also showed a significant decrease in PGF2 in the urine compared to the placebo group after 4 weeks of ingestion.

> In conclusion, NVP-1703 can reduce the secretion of IL-4, IL-5, IL-13, IgE, PGD2, and LTE4 and induce IL-10 expression by suppressing the activation of mast cells, eosinophils, Th2 cells, and B cells through the induction of Treg cells, resulting in the attenuation of allergic rhinitis symptoms.
